Neuregulin 1 confers neuroprotection in SOD1-linked amyotrophic lateral sclerosis mice via restoration of C-boutons of spinal motor neurons by Jurate Lasiene et al.
RESEARCH Open Access
Neuregulin 1 confers neuroprotection in
SOD1-linked amyotrophic lateral sclerosis
mice via restoration of C-boutons of spinal
motor neurons
Jurate Lasiene1†, Okiru Komine2†, Noriko Fujimori-Tonou1,3†, Berit Powers4,5, Fumito Endo2, Seiji Watanabe2,
Jin Shijie2, John Ravits6, Philip Horner4, Hidemi Misawa7 and Koji Yamanaka1,2*
Abstract
Introduction: Increasing evidence implicates the role of the cell types surrounding motor neurons, such as
interneurons and glial cells, in non-cell autonomous neurodegeneration of amyotrophic lateral sclerosis (ALS). C-boutons,
the large cholinergic synapses that innervate spinal α-motor neurons to control their excitability, are progressively lost
from motor neurons in both human ALS and mutant Cu/Zn superoxide dismutase 1 (SOD1)-ALS mice. Neuregulin-1
(NRG1), a trophic factor implicated in neural development, transmission, and synaptic plasticity, has been reported
to localize in the synapse of C-boutons. However, the roles of NRG1 in maintenance of motor neuron health and
activity, as well as the functional consequences of its alteration in motor neuron disease, are not fully understood.
Results: NRG1 was localized to the post-synaptic face of C-boutons and its expression was significantly lost in
SOD1-ALS mice and human ALS patients. Losses of NRG1 expression and C-boutons occured almost
contemporaneously in SOD1-ALS mice. In addition, expressions of ErbB3 and ErbB4, receptors for NRG1, were
reduced in the motor neurons of SOD1-ALS mice. Furthermore, viral-mediated delivery of type III-NRG1 to the
spinal cord restored the number of C-boutons and extended the survival time of SOD1-ALS mice.
Conclusions: These results suggest that maintenance of NRG1-ErbB4/3 axis by supplementation of NRG1 confers
neuroprotection in motor neuron disease, partly through the maintenance of C-boutons of spinal motor neurons.
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Introduction
A key characteristic of neurodegenerative diseases is the
degeneration of a specific type of neuron. In amyotrophic
lateral sclerosis (ALS), an adult-onset neurodegenerative
disease, motor neurons are specifically affected during the
degenerative process. While the majority of ALS cases are
of sporadic etiology, approximately 10 % of cases are
inherited, and dominant mutations in the gene for cop-
per/zinc superoxide dismutase (SOD1) are a frequent
cause of inherited ALS. Using transgenic rodent and fish
models of SOD1-linked ALS that recapitulate specific
motor neuron degeneration, the cell types surrounding
motor neurons, including glial cells and interneurons,
have been shown to be actively involved in ALS pathogen-
esis [1–4].
C-boutons are large cholinergic terminals that synapse
onto spinal α-motor neurons, which are highly vulner-
able in ALS. The origin of C-boutons was recently iden-
tified as partition cells, cholinergic interneurons located
vicinity of the spinal central canal, and their role uncov-
ered as critical modulators of motor neuron activity dur-
ing locomotor behavior [5–7]. Intriguingly, C-boutons
do not terminate on the cranial motor neurons innervat-
ing eye muscles, which are spared in ALS. In sporadic
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ALS patients, losses of C-boutons on spinal motor neu-
rons remaining at autopsy were documented [8]. How-
ever, alteration of C-boutons in symptomatic mutant
SOD1 mice reported by several groups was variable: one
report showed a significant loss of C-boutons [9], while
the other groups reported moderate [10] or marginal
[11, 12] loss of C-boutons. Moreover, the reports dem-
onstrate early reduction of choline acetyltransferase
(ChAT) at C-boutons in presymptomatic SOD1G93A
mice [13] and reduced immunoreactivity for vesicular
acetylcholine transporter (VAChT) in motor neurons in
80 day-old, presymptomatic SOD1G93A mice [14]. Others
demonstrate a decrease in VAChT-positive boutons fol-
lowing symptomatic onset in mouse models [9, 15]. These
reports suggest that C-boutons could be linked to patho-
mechanism of ALS, however, existing evidence of altered
numbers and roles of C-boutons in ALS patients and
models is contradictory and largely inconclusive.
Neuregulin 1 (NRG1), is an epidermal growth factor
(EGF)-like trophic factor implicated in neural develop-
ment, synaptic transmission and plasticity, Schwann cell
differentiation, and the regulation of myelin sheath thick-
ness [16, 17]. NRG1 is localized to the cholinergic synapses
(C-boutons) that innervate motor neuron somata and
proximal processes [18] and modulate the activity of motor
neurons. In addition to known involvement of NRG1 in
schizophrenia [17], recent data suggests the possible in-
volvement of NRG1 in ALS. A dominant mutation in the
gene for ErbB4, encoding a receptor for NRG1, is causative
for familial ALS type 19 [19]. Moreover, although the re-
sults are not entirely consistent with each other, altered ex-
pression of NRG1 has been reported in the lesions of
mutant SOD1 mice [9, 20]. These accumulating data sug-
gest that NRG1 could participate in stabilizing synapses or
in regulating activity of motor neurons at C-boutons and
that its dysregulation could contribute to motor neuron
degeneration in ALS. However, its localization in normal
and diseased motor neurons and whether NRG1 has neu-
roprotective properties are not fully understood.
In this study, we found that NRG1 was localized in the
post-synaptic face of C-boutons and its expression was
significantly lost in SOD1-linked ALS mice and human
ALS patients. Viral-mediated delivery of type III NRG1
restored the number of C-boutons and extended the
survival time of SOD1G93A mice. These results suggest
that NRG1 exerts neuroprotective properties in motor
neuron disease partly through maintenance of C-boutons
of spinal motor neurons.
Materials and Methods
Transgenic mouse lines and survival experiments
Transgenic mouse lines expressing human SOD1 gene with
ALS-linked mutations, SOD1G93A [B6.Cg-Tg(SOD1*G93
A)1Gur/J] or SOD1G85R [B6.Cg-Tg(SOD1*G85R)148Dwc/J]
were obtained from Jackson laboratory or were gifts from
Dr. Don Cleveland (University of California, San Diego).
Onset and survival times for mutant SOD1 mice are 100–
105 and 150–160 days old for SOD1G93A mice, and 11–12
and 12–13 months old for SOD1G85R mice, respectively.
Genotyping of SOD1 transgenic mice was identified
by polymerase chain reaction (PCR) as previously de-
scribed [21].
All animal procedures were conducted in accordance
with the guidelines of the Animal Use and Care Commit-
tees of Nagoya University, Keio University and RIKEN.
Transgenic animals are always compared with their non-
transgenic littermates to minimize the effects of different
genetic background. Times of disease onset and end stage
were determined respectively as the time when mice had
started losing the maximum body weight and when animals
failed in righting themselves within 20 s when placed on
their backs, an endpoint commonly used for mutant SOD1
expressing mice which is compliant with the requirements
of the Animal Use and Care Committee. Statistical analysis
of onset and survival time was performed with Gehan-
Breslow-Wilcoxon test by using GraphPad Prism (Graph-
Pad Software, USA).
Postmortem human tissues
Spinal cord tissues from three patients with sporadic
ALS and three control patients who died of causes other
than ALS (patient data summarized in Table 1) were ob-
tained by autopsy with informed consent. The diagnosis
of ALS was confirmed by El Escorial diagnostic criteria
as defined by the World Federation of Neurology. These
ALS patients were confirmed to be negative for C9Orf72
expansion or other known causes of inherited ALS. The
collection of tissues and their use in this study was
approved by the institutional review board for research
ethics of Benaroya Research Institute, Seattle, WA, USA.
Antibodies
Following primary antibodies were used in the study:
anti-NRG1 (rabbit; 1:500, sc-348, Santa Cruz, USA),
anti-VAChT (guinea pig; 1:250, AB1588, Merck
Millipore, USA), anti-ChAT (goat; 1:100, AB144P, Merck
Millipore), anti-NeuN (mouse; 1:1000, MAB377, Merck
Millipore), anti-Kv2.1 (mouse; 1:250, clone K89/34,
NeuroMab, USA), anti m2 muscarinic receptor (rat;
1:500, MAB367, Merck Millipore), anti-GFAP (mouse;
1:500, G3893, Sigma-Aldrich, USA), anti-Iba1 (rabbit;
1:500, 019-19741, Wako, Japan), anti-ErbB3 (rabbit; 1:50,
sc-285, Santa Cruz), and anti-ErbB4 (mouse; 1:300, MS-
270-P0, Thermo Fisher Scientific, USA).
Immunofluorescence
Immunofluorescence was performed as described previ-
ously [21]. For human spinal cords, 20 μm sections were
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made of fresh frozen tissue, air dried on slides, and fixed
in ice-cold acetone for 10 min. In brief, after blocking for
1 h, the sections were incubated with primary antibodies
overnight at 4 °C. Bound antibodies were detected with
appropriate Alexa Fluor-conjugated anti-rabbit, mouse,
rat, goat, or guinea pig IgG antibodies (Thermo Fisher
Scientific). For detecting ErbB3 antibody, Cy3-conjugated
anti-rabbit IgG antibody (Jackson Laboratories, USA) was
used. Immunostained images were obtained by confocal
laser scanning microscopy (LSM 5 Exciter, LSM-700; Carl
Zeiss AG, Germany) and the equipped software (Zen; Carl
Zeiss AG).
Quantification of NRG1, VAChT-immunopositive puncta
and the size of motor neurons
Sections of mouse lumbar spinal cords were triple-
immunostained with the antibodies for NRG1, VAChT, and
NeuN and appropriate secondaries. After obtaining three-
dimensional images of immunostained lumbar spinal cord
sections of mice, 30 to 60 motor neurons from two to five
animals per genotype were quantified for NRG1- and
VAChT- immunoreactivity surrounding motor neurons.
Lumbar motor neurons were positively identified as
large, NeuN-positive neurons surrounded by VAChT-
positive puncta located in the anterior horn. Quantified
data were statistically analyzed with one-way ANOVA
with Bonferroni’s Multiple Comparison test or Kruskal-
Wallis test with Dunn’s Multiple Comparison test.
For human tissue, spinal cord sections were stained
with the antibodies for NRG1 and ChAT. After obtain-
ing three-dimensional images of immunostained spinal
cord sections, a minimum of 15–20 motor neurons
from each of 3 ALS patients at each spinal level (cer-
vical, thoracic, and lumbar) were quantified for
NRG1-positive puncta and compared to individuals
who died of causes unrelated to ALS. Data was statis-
tically analyzed by one-way ANOVA with Bonferroni
correction.
To analyze the size of motor neurons, total of 60
lumbar motor neurons immunopositive for anti-ChAT
or anti-NeuN antibody from three mice per each group
was quantified for the surface area by using the Image J
software.
Preparation and stereotaxic injection of recombinant
adeno-associated virus (AAV) encoding NRG1
The adeno-associated viral expression constructs chimeric
rAAV1/2-CAG-NRG1-IRES-EGFP-WPRE (woodchuck
post-translational regulatory element) were constructed
by subcloning Type I-NRG1 or Type III (SMDF)-NRG1
cDNA into the rAAV1/2 cassette. Viral vectors were pack-
aged and purified at a high titer suitable for expression in
mouse spinal cords (GeneDetect, New Zealand). The
stereotaxic injections of rAAV into SOD1G93A mice
were performed at 65 days old or 105 days old. The
mice were anesthetized by intraperitoneal injection of
pentobarbital, then 0.5 μl of rAAV was injected
bilaterally into the lumbar ventral spinal cord at
Th13, L1, and L2 levels of the spine for a total vol-
ume of 3 μl, equivalent to 3.6 × 108 viral particles.
Similar quantities of rAAV-GFP were also injected
into a control group of mice.
Reverse transcribed PCR
Total RNA was extracted from lumbar spinal cords using
TRIzol (Thermo Fisher Scientific) and purified using an
RNeasy Mini Kit (Qiagen, Valencia, USA). cDNA was syn-
thesized from total RNA using PrimeScript II 1st strand
cDNA Synthesis Kit (Takara Bio, Japan). Quantitative RT-
PCR was performed using SYBR Premix Ex Taq II (Takara
Bio) using gene specific primers as follows. Type III-
NRG1: GAGGTGAGAACACCCAAGTCA, TGGTCCCA
GTCGTGGATGTAG; Type I-NRG1: TGCCAACAT
CACCATTGTTGA, GGACACATAGGGTCTTTCAGTT
GA [22]. Primers for Type III-NRG1 were also used for
semi-quantitative PCR.
Table 1 Detail of the patients. The spinal cord specimens from three sporadic ALS and control patients with other diseases were
analyzed. Disease controls include Parkinson’s diseases, cerebrovascular disease, and liver failure
ID Diagnosis Clinical information Time of
sampling after
death (hrs)
Patient ID. Primary Diagnosis Secondary
Diagnosis
Age at death Gender Site of Onset Disease Course (yrs)
ALS-43 SALS 74 Male Respiratory & trunk 1.75 6
ALS-47 SALS FTD 65 Female Bulbar 1.25 7
ALS-60 SALS 58 Female Bulbar 3 3
Control-19 Parkinson's disease 80 Female NA NA 2.5
Control-20 Basilar artery occlusion 38 Male NA NA 6
Control-44 Liver Failure 80 Female NA NA 5
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Results
Neuregulin 1 is localized to the post-synaptic face of
C-bouton in mouse spinal motor neurons
To investigate the localization of neuregulin 1 (NRG1)
in C-boutons of spinal motor neurons, detailed immuno-
fluorescence analysis was performed. Immunoreactivity
for NRG1 showed punctate staining surrounding somata
and proximal processes of large motor neurons in mouse
lumbar spinal cords (Fig. 1a, b). NRG1 puncta were pre-
dominantly co-localized with Kv2.1, a post-synaptic
marker for cholinergic synapses on motor neurons (Fig. 1c,
d), suggesting the post-synaptic localization of NRG1 on
the C-bouton. The post-synaptic localization of NRG1 on
the C-bouton was further confirmed by its co-localization
with m2 muscarinic acetylcholine receptors on motor
neurons (Fig. 1e–h). Vesicular acetylcholine transporter
(VAChT) is mainly localized on cholinergic synaptic
vesicle membranes and is used as a marker of C-bouton
synaptic terminals [18, 23]. Although NRG1 was localized
to close vicinity of VAChT-immunoreactivity, NRG1
Fig. 1 Neuregulin-1 is localized in the post-synaptic face of C-bouton in the mouse spinal motor neurons. (a) Domain structures for murine
Neuregulin-1 (NRG1) type III (Type III-β1a, based on gene accession number: NM 178591) and type I (Type I-β1a, based on gene accession
number: AY648976). The anti-NRG1 antibody used in this study recognizes both Type I and Type III NRG1. Arrows indicate the sites of primers used
for quantitative PCR in Fig. 2. (b–d) Representative images of lumbar spinal cord sections from 4 month old wild-type mice (C57BL/6) stained with
the antibodies for neuregulin-1 (NRG1) (b), Kv2.1 (c), along with the merged image stained by NRG-1, Kv2.1, and choline acetyltransferase (ChAT)
antibodies (d). Inset showed magnified image of C-bouton indicated by asterisk (d). (e–h) Representative images of lumbar spinal cord sections
from 4 month old wild-type mice stained with the antibodies for neuregulin-1 (NRG1) (e), m2 muscarinic acetylcholine receptor (m2) (f), along
with the merged image stained with NRG1, m2, and ChAT antibodies (g). Magnified Z-axis images of the C-bouton in (e–g: arrow) (h). (i) Representative
image of motor neuron stained by NRG1, VAChT, and NeuN antibodies. (j) Magnified Z axis-images of the C-bouton in (e: asterisk). Bar: 20 μm (b–d, i),
12.5 μm (e–g)
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immunoreactivity did not overlap with VAChT at C-
boutons (Fig. 1i, j). These results suggest that NRG1 is
specifically localized to the post-synaptic face of C-
boutons in mouse spinal motor neurons.
Age-dependent loss of NRG1 in lumbar spinal motor
neurons of SOD1G93A and SOD1G85R mice
Several studies have investigated the number and morph-
ology of C-boutons synapsing onto spinal motor neurons
of SOD1-ALS mice by using VAChT immunoreactivities or
ultrastructural analysis, revealing that C-boutons are mostly
preserved until the symptomatic phase [10–12]. To exam-
ine whether NRG1 expression is affected in SOD1-ALS
mice, we analyzed NRG1-positive puncta in lumbar motor
neurons of SOD1G93A and SOD1G85R mice, the rodent
models widely used for inherited ALS (Fig. 2a–l). In both
mutant SOD1 mice, the numbers of NRG1-positive puncta
were decreased at symptomatic stages compared with age-
matched, non-transgenic littermates (Fig. 2m, n). The num-
bers of VAChT-immunopositive puncta, which reflect the
number of C-boutons, were also decreased in the symp-
tomatic SOD1G93A and SOD1G85R mice (Additional file 1:
Fig. S1). The mRNA levels for type I and type III NRG1
were also decreased in the lumbar spinal cords of symp-
tomatic SOD1G93A and SOD1G85R mice in an age-
dependent manner (Fig. 2o, p). These results indicate that
both NRG1 transcript and protein levels were decreased in
the lumbar spinal cords of symptomatic SOD1G85R and
SOD1G93A mice.
Loss of NRG1-positive puncta in the spinal motor neurons
of sporadic ALS patients
Previous reports demonstrated a decreased number of C-
boutons in postmortem spinal motor neurons in sporadic
ALS [8]. However, it is not established whether NRG1
localization and loss of its expression follow a similar pat-
tern in sporadic ALS to that of ALS mice. We found that
NRG1 was localized to the surface of motor neuron somata
and proximal processes in human spinal cord (Fig. 3a), con-
sistent with its localization in mice. Furthermore, NRG1
puncta surrounding motor neurons were substantially lost
in sporadic ALS (Fig. 3b). Examination of cervical, thoracic,
and lumbar spinal cord tissues from three sporadic ALS
and control patients revealed that the average number of
NRG1 puncta per motor neuron was significantly reduced
in the spinal motor neurons of sporadic ALS at all spinal
levels (Fig. 3c).
Viral-mediated delivery of type III NRG1 extends the
survival time of SOD1G93A mice
Loss of NRG1 puncta at C-boutons of motor neurons in
both sporadic ALS patients and two distinct lines of
SOD1-ALS mice prompted us to test whether NRG1 has
a neuroprotective potential for motor neuron disease.
Adeno-associated virus (AAV) encoding full-length type
III and type I mouse NRG1 were administered in lumbar
spinal cords of SOD1G93A mice (Fig. 1a). Overexpression
of NRG1 by AAV-NRG1 was confirmed by elevated levels
of NRG1 transcripts when compared with control injec-
tion of AAV-GFP (Fig. 4a). Presymptomatic administra-
tion of AAV-Type III-NRG1 did not alter the time of
disease onset (Fig. 4c, e), however, significantly extended
the survival time of SOD1G93A mice (AAV-Type III-
NRG1: 164.2 ± 7.4 days; AAV-GFP: 154.2 ± 10.4 days;
Fig. 4b, d). Administration of Type I-NRG1 also showed
tendency to extend survival time, however, it did not reach
statistical significance (AAV-Type I-NRG1: 161.4 ±
14.0 days; Fig. 4b–e). Symptomatic treatment with AAV-
NRG1 had a marginal effect on extending survival time
(AAV-Type I-NRG1: 165.3 ± 13.1 days; AAV-Type-III-
NRG1: 162.5 ± 12.5 days; AAV-GFP: 159.5 ± 11.8 days;
Additional file 1: Fig. S2). These results suggest a neuro-
protective role of NRG1 in motor neuron degeneration.
Viral-mediated delivery of NRG1 restores the number of
NRG1-positive puncta and increases the size of motor
neuron somata in SOD1G93A mice
To uncover the neuroprotective mechanism of NRG1 in
SOD1G93A mice, we quantified the number of NRG1-
positive puncta surrounding lumbar motor neurons. In
comparison with GFP-transduced animals, Type III-NRG1
administration restored the number of NRG1-
immunoreactive puncta as well as C-boutons immunoreac-
tive for VAChT in lumbar motor neurons (Fig. 5a–e). In
addition, the size of remaining motor neurons showed a
trend toward enlargement in Type III-NRG1-trasnduced
mice compared to GFP-transduced mice (Fig. 5f). Activa-
tion of astrocytes and microglia was evaluated by immuno-
staining for glial fibrillary acidic protein (GFAP) and Iba1,
respectively, revealing no significant difference in the degree
of glial activation in endstage SOD1G93A mice treated with
Type III-NRG1 or GFP (Fig. 5g–j). Marginal changes in
glial cells in SOD1G93A mice overexpressing Type III-
NRG1 may be attributed to the predominant expression of
exogenous NRG1 in the neurons (Additional file 1: Fig. S3).
ErbB4 and ErbB3 expressions are reduced in SOD1G93A
motor neurons
Dominant mutations in the gene for ErbB4, encoding a re-
ceptor for NRG1, is causative for inherited ALS (ALS19)
[19]. Considering that NRG1 expression in SOD1-ALS
models is linked to neurodegeneration, it is of interest to
examine whether ErbB4 is dysregulated in SOD1-ALS
models. In spinal cords of wild-type mice, we observed
punctate ErbB4 staining on large spinal neurons sur-
rounded by VAChT-immunopositive puncta, indicating that
ErbB4 is enriched in motor neurons (Fig. 6a, c, e). Double
immunofluorescence studies revealed that ErbB4 was co-
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localized neither with NRG1 nor VAChT (Fig. 6a–d). These
results indicate that ErbB4 is not localized in C-boutons
but is predominantly expressed in the membrane
compartment of spinal motor neurons. Compared with
wild-type mice (Fig. 6e), immunoreactivity of ErbB4 is de-
creased in some motor neurons of SOD1G93A mice around
Fig. 2 Age-dependent losses of NRG1 in the lumbar spinal cord of SOD1G93A and SOD1G85R mice. (a–l) Representative images of the lumbar
spinal cord of 4 month old wild-type (WT) mice (a–c), SOD1G93A (G93A) mice (d–f), 12 month old wild-type (WT) mice (g–i), and SOD1G85R (G85R)
mice (j–l) stained with the antibodies for NRG1 (a, d, g, j), VAChT (b, e, h, k), and NRG1/VAChT/NeuN (c, f, i, l). Bar: 50 μm (m, n) Quantification of
the number of NRG1-positive puncta per motor neuron in wild-type and SOD1G93A mice (m) or wild-type and SOD1G85R mice (n) at indicated
ages. ES denotes endstage. At least 30 (SOD1G93A) or 60 (SOD1G85R) motor neurons from mutant SOD1 (n = 3−5) or wild-type mice (n = 2−3) were
analyzed for NRG1-positive puncta. Fewer number of motor neurons were analyzed in symptomatic SOD1G93A mice due to loss of well-defined
shaped motor neurons. Red bars represent average from both groups. ***: p < 0.001, ****: p < 0.0001 (Dunn’s Multiple Comparison test (m) or
Bonferroni’s Multiple Comparison test (n)). (o, p) mRNA levels of NRG1 type III (o) and type I (p) in the lumbar spinal cords of wild-type, SOD1G93A,
and SOD1G85R mice at indicated ages. The mean mRNA levels of NRG1 isoforms relative to the ones of wild-type mice at 3 month old (left) or
6 month old (right) obtained by quantitative PCR analysis were plotted. *: p <0.05, ***: p <0.001 (Tukey’s multiple comparison test). Error bars
denote SD
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the time of disease onset (3–3.5 months old, Fig. 6f, g),
followed by more significant losses of ErbB4 in the
remaining SOD1G93A motor neurons at symptomatic stages
(Fig. 6h). Intriguingly, we observed a partial preservation of
NRG1/VAChT puncta in the SOD1G93A motor neurons
with diminished ErbB4 expressions (Fig. 6f–h, arrows). We
also examined the expression of ErbB3, another receptor
for NRG1. ErbB3 is known to be predominantly expressed
in oligodendrocytes, Schwann cells, and dorsal root ganglia
[24]. However, our staining revealed that ErbB3 also
expressed in the somata of neurons including motor neu-
rons in the adult mouse spinal cord as previously reported
in rat (Fig. 7a–e) [25]. In addition, ErbB3 also expressed in
astrocytes (Fig. 7d), and partition cells (Fig. 7d, arrowhead
and inset, Additional file 1: Fig. S4). Although ErbB3
expressed in almost all spinal neurons, it was not co-
localized with VAChT (Fig. 7a, b). As like ErbB4, ErbB3
expression was reduced in some motor neurons of
SOD1G93A mice around the time of disease onset (Fig. 7f,
g), and diminished further toward the symptomatic stage
(Fig. 7h). These data suggest that the losses of ErbB4 and
ErbB3 were observed in SOD1G93A motor neurons at dis-
ease onset and preceded the decreased expressions of
VAChTand NRG1 puncta.
Discussion
Recently, localization of NRG1 has been documented at
cholinergic synapses that innervate spinal motor neu-
rons, called C-boutons [18]. Alterations in the numbers
or sizes of C-boutons have been reported in ALS pa-
tients and mouse models [8–12, 26, 27]. This, together
with the recent discovery that a mutation in ErbB4, a
component of NRG1 receptors, is causative for ALS19
[19], suggests that disruption of the NRG1-ErbB4 axis
Fig. 3 Loss of NRG1-positive puncta in the spinal motor neurons of sporadic ALS and control patients. (a, b) Representative images of lumbar
spinal cord of the control (a) and sporadic ALS patients (b) stained with NRG1 (green), ChAT (red), and DAPI (blue). Magnification: 20x. (c) Quantification
of mean NRG1-positive puncta per motor neuron from indicated regions of spinal cords from control and ALS patients (n = 3, each). **: p <0.01 by
one-way ANOVA
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could play a role in ALS neurodegeneration. In this
study, we determined that NRG1 is enriched at the post-
synaptic face of C-boutons in spinal motor neurons. We
also found that expression of NRG1 was significantly
lost in symptomatic ALS mice and human ALS, and that
expressions of ErbB4 and ErbB3 are reduced in the
motor neurons of ALS mice around the disease onset.
Finally, we report that viral-mediated delivery of type III
NRG1 restored the number of C-boutons and extended
survival times of SOD1G93A mice. These results suggest
that supplementation of NRG1 is capable of ameliorat-
ing motor neuron disease partly through maintenance of
C-boutons of spinal motor neurons.
Using immunoreactivity of VAChT, alteration of C-
boutons in mutant SOD1 mice reported by the several
groups was inconclusive [9–12]. Our analyses revealed
moderate loss of C-boutons in two distinct strains of
symptomatic mutant SOD1 mice, SOD1G93A and
SOD1G85R. Discrepancy among these previous studies
may be attributed to a difference in methods and choice
of motor neurons for quantification. Since moderate
losses of C-boutons and NRG1 expression in motor neu-
rons were observed almost contemporaneously, reduc-
tion of NRG1 in motor neurons may occur not through
dysfunction of C-bouton mediated cholinergic inputs
but through the general impairment of pre-degenerating
motor neurons. In addition, although Song and col-
league reported that type I NRG1 mRNA was elevated
in end-stage SOD1G93A mice [20], we observed the levels
of both type I and type III NRG1 mRNAs were reduced
in the spinal cord of symptomatic SOD1G93A and
SOD1G85R mice. Discrepancy between two studies might
be partly attributed to the genetic background of
SOD1G93A mice used in the study by Song and col-
league. Future studies will reveal the detailed expression
profiles of NRG1 splice variants in ALS mice.
Our detailed immunofluorescence study revealed that
NRG1 immunoreactivity co-localized with the post-
Fig. 4 Virus-mediated delivery of NRG1 extends the survival time of SOD1G93A mice. (a) Semi-quantitative reverse transcription PCR for Type III-
NRG1 and β-actin mRNA in AAV-Type III-NRG1 injected- and AAV-GFP injected- spinal cords. This PCR reaction amplifies endogenous NRG1 as well
(GFP). (b, c) Kaplan-Meier curve of onset (c) and survival time (b) for SOD1G93A mice injected with AAV-Type III-NRG1 (red) (survival time: male = 3,
female = 8, onset: male = 5, female = 10), AAV-Type I-NRG1 (blue) (survival time: male = 4, female = 6, onset: male = 6, female = 8), or AAV-GFP
(black) (survival time: male = 4, female = 7, onset: male = 6, female = 9). (d, e) Mean survival (d) and onset time (e) of SOD1G93A mice injected with
indicated virus are plotted. Error bars denote SD. **: p < 0.05 (Gehan-Breslow-Wilcoxon test)
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synaptic proteins, m2 muscarinic receptors and
voltage-gated Kv2.1 channels, and not with the pre-
synaptic protein, VAChT. These findings indicated that
NRG1 was localized in the post-synaptic face of C-
boutons, a finding similar to the one reported by
Gallart-Palau et al [9]. This indicates that the source of
NRG1 expression is motor neurons themselves. In the
nervous system, NRG1 plays multiple roles in neural
development, synaptic plasticity and transmission,
Schwann cell differentiation, and regulation of myelin
sheath thickness [16, 17]. Although one group reported
ErbB4 receptor is localized in presynaptic terminal of
C-boutons [9], our staining revealed that ErbB4 is not
co-localized with VAChT. Instead, ErbB4 immunoreac-
tivity is mainly observed in motor neuron somata with
punctate staining. Moreover, we observed for the first
time that ErbB4 and ErbB3 expressions in motor neu-
rons decreased just prior to the losses of NRG1/VAChT
Fig. 5 Virus-mediated delivery of Type III-NRG1 restores the number of NRG1-positive puncta and increases the size of motor neuron soma in
SOD1G93A mice. (a–c) Representative images for the lumbar motor neurons of SOD1G93A mice injected GFP (a) or Type III-NRG1 (b, c) encoding
AAV. The lumbar spinal cord sections were stained with antibodies for NRG1 (red) and ChAT (blue). Bar: 50 μm. (d, e) Quantification for the
average number of NRG1-positive puncta (d) or VAChT-positive C-boutons (e) per motor neuron soma. Sixty motor neurons from GFP- or Type
III-NRG1-injected symptomatic SOD1G93A mice (n = 3 each) were analyzed for NRG1-positive puncta. The bars indicate averages for both
groups. ***: p < 0.001, unpaired t-test. (f) Cumulative probability plot for the size of motor neuron soma. Sixty VAChT-positive lumbar motor
neurons from SOD1G93A injected with AAV-GFP (black) or AAV-Type III-NRG1 (red) were analyzed for the surface area of soma (n = 3 per each
group). Non-statistical significance among two groups, Kolmogorov-Smirnov test. (g–j) Representative images for the lumbar spinal cord
sections of SOD1G93A mice injected with AAV-GFP (g, i) or AAV-Type III-NRG1 (h, j) stained with antibodies for GFAP (g, h) or Iba1 (i, j).
Bar: 50 μm
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puncta in mutant SOD1 mice, despite that the mechan-
ism of progressive loss of ErbB4/ErbB3 remains un-
clear. Progressive losses of ErbB4/B3 in the motor
neurons may explain that neuroprotection was achieved
by the administration of type III-NRG1 at the presymp-
tomatic stage, not at the symptomatic stage.
Previous studies showed that the number of C-boutons
per motor neuron was transiently increased in P8-P30
SOD1G93A mice [12, 27] and that C-boutons become
enlarged in response to motor neuron damage, leading to
increased excitability of motor neurons [12, 26]. These
phenomena were interpreted as a compensatory mechan-
ism to maintain the function of motor neurons. Our study
partially supports this hypothesis, since viral-mediated
supplementation of type III-NRG1 provided neuroprotec-
tion by increasing the number of C-boutons, rather than
the size. On the other hand, our immunostaining revealed
that ErbB4 receptor was mainly localized to the motor
neuron membrane rather than to partition cells, while
ErbB3 expressed in the all spinal neurons including the
partition cells. Considering that NRG1 and ErbB4 are se-
lectively localized to the motor neurons in the spinal cord,
we propose that NRG1 may provide neuroprotection to
motor neurons directly through ErbB4 receptors in motor
neuron somata. In many cases, NRG1-ErbB signaling is
observed at the synaptic terminal, the interface of nerve
Fig. 6 Reduction of ErbB4 expression precedes loss of NRG1 puncta in the lumbar motor neurons of SOD1G93A mice. (a–d) The lumbar spinal
cord sections from 5 months old wild-type mice were stained with the antibodies for ErbB4, VAChT, and NRG1. The representative images for
motor neurons stained with NRG1/ErbB4 (a) or VAChT/ErbB4 (c) with corresponding magnified Z axis-images of the C-bouton (b, d, arrows). Bars:
10 μm. (e–h) The lumbar spinal cord sections from 5 months old wild-type (WT; e) or SOD1G93A mice at 3 (f), 3.5 (g) and 5 months old (h) were
stained with the antibodies for ErbB4, VAChT, and NRG1. Representative images in the anterior horn area were shown with the merged images.
Arrows indicate the motor neurons surrounded by VAChT- and NRG1-positive puncta showed diminished expressions of ErbB4. Bars: 50 μm
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axon and Schwann cells, or neuromuscular junction [24].
However, autocrine signaling of NRG1-ErbB is observed
in Schwann cell differentiation and remyelination or
tumor growth [28–30]. In addition, NRG1 is known to
exert neuroprotection through ErbB4 receptor in MPTP
models of Parkinson’s disease [31] and cerebral ischemia
[32]. Therefore, NRG1 may protect motor neurons
through ErbB4 by an autocrine fashion.
Alternatively, it is possible that NRG1 confers neuropro-
tection indirectly via ErbB3 in the partition cells or their
neighboring astrocytes and oligodendrocytes to maintain
the number and integrity of C-boutons. Several reports
have described the roles of interneurons in SOD1-ALS
models. Glycinergic interneurons are degenerated prior to
symptomatic onset in SOD1G93A mice, while no signifi-
cant change in other interneurons, such as GABAergic
neurons was found [15]. Although only modest degrees of
changes in cholinergic interneurons has been reported, in-
cluding herein, further examination of the role of inter-
neurons in non-cell autonomous aspects of motor
neurodegeneration will provide a more complete picture
of pathomechanisms in ALS.
Fig. 7 Reduction of ErbB3 expression in the lumbar motor neurons of SOD1G93A mice. (a–d) The lumbar spinal cord sections from 5 months old
wild-type mice were stained with the antibodies for ErbB3, VAChT, GFAP, and NeuN. The representative images for motor neurons stained with
VAChT/ErbB3 (a) with corresponding magnified Z axis-images of the C-bouton (b, arrow). Bar: 10 μm. (c, d) Images for the lumbar spinal cord
sections from 5 months old wild-type mice stained with the antibodies for ErbB3 and NeuN (c), or ErbB3, ChAT, and GFAP (d). Arrowhead and
inset indicate ErbB3 expressions in ChAT-positive partition cells and their magnified image, respectively. Bars: 200 μm (c, d). (e–h) The lumbar
spinal cord sections from 5 months old wild-type (WT; e) or SOD1G93A mice at 3 (f), 3.5 (g) and 5 months old (h) were stained with the antibodies
for ErbB3, VAChT, and NeuN. Representative images in the anterior horn area were shown with the merged images. Arrows indicate the motor
neurons surrounded by VAChT-positive puncta showed diminished levels of ErbB3. Arrowheads show the VAChT-negative, non-motor neurons
with preserved ErbB3 expressions in SOD1G93A mice. Bar: 50 μm (e–h)
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Conclusions
Our study is the first to demonstrate dysregulation of
the NRG1-ErbB4/3 axis in both human and mouse ALS
and to provide support for NRG1 supplementation as a
possible therapeutic option for motor neuron disease.
Considering that NRG1 conferred increased survival in
SOD1-ALS mice and its receptors ErbB4/3 were dysreg-
ulated, maintenance of the NRG1-ErbB4/3 axis might be
crucial for mitigation of SOD1-ALS. Lastly, since NRG1
was also lost in sporadic ALS motor neurons, it may also
play a role in motor neuron health in non-SOD1 associ-
ated ALS.
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